94-2089. Government-Owned Inventions; Availability for Licensing

[Federal Register Volume 59, Number 20 (Monday, January 31, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-2089]


[[Page Unknown]]

[Federal Register: January 31, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

 

Government-Owned Inventions; Availability for Licensing

Agency: National Institutes of Health, HHS.

Action: Notice.

-----------------------------------------------------------------------

Summary: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing in the U.S. (and in foreign 
markets) in accordance with 35 U.S.C. 207 to achieve expeditious 
commercialization of results of federally funded research and 
development.
    U.S. Patent Application Number 07/941,371, filed September 3, 1992, 
and entitled ``Self-Assembling Recombinant Papillomavirus Capsid 
Proteins''--The invention described in this application and its 
continuation application (U.S. Patent Application Number 08/032,869, 
filed March 16, 1993) is an enzyme-linked immunosorbent assay (ELISA) 
to detect humoral immunity response to papillomavirus infection in 
humans and other vertebrates. Assays have thus far been produced based 
upon serum immunoglobulin recognition of conformation epitopes of 
papillomavirus virion proteins on purified virus-like particles for 
HPV16, which is the HPV type most frequently found in cervical cancer. 
Assays for other high-risk cervical cancer HPV types (HPV18, HPV31, and 
HPV45) and for low-risk genital HPV types (HPV6 and HPV11) are under 
development using the same technology. The ELISA test for the genital 
HPV types may be useful as an adjunct to the Papanicolaou (PAP) test 
for identifying women with an increased risk of developing cervical 
cancer.
    The patent applications covering this invention are available for 
licensing for diagnostic uses.

Addresses: Licensing information and copies of this U.S. patent 
application may be obtained by writing to Mark D. Hankins at the Office 
of Technology Transfer, National Institutes of Health, Box OTT, 
Bethesda, Maryland 20892 (telephone [phone]; fax [phone]). A 
signed Confidential Disclosure Agreement will be required to receive a 
copy of the patent application.

    Dated: January 13, 1994.
Donald P. Christoferson,
Acting Director, Office of Technology Transfer.
[FR Doc. 94-2089 Filed 1-28-94; 8:45 am]
BILLING CODE 4140-01-M